ITI 333
Alternative Names: ITI-333Latest Information Update: 15 Apr 2025
At a glance
- Originator Intra-Cellular Therapies
- Class Antidepressants; Antipsychotics; Anxiolytics; Drug withdrawal therapies; Mood stabilisers; Opioid analgesics; Small molecules
- Mechanism of Action Dopamine D1 receptor antagonists; Opioid receptor agonists; Serotonin 5-HT2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anxiety disorders; Mood disorders; Pain; Substance-related disorders
Most Recent Events
- 02 Apr 2025 Intra-Cellular Therapies has been acquired by Johnson & Johnson
- 04 Mar 2025 ITI 333 is still in phase-I trials in Substance-related disorders (In volunteers) in USA (PO)
- 31 Dec 2024 Discontinued - Phase-I for Substance-related disorders (In volunteers) in USA (PO), before December 2024 (Intra-Cellular Therapies pipeline, March 2025)